Drug · CHEMBL503
LOVASTATIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. LOVASTATIN. Drugs and targets, record CHEMBL503. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL503
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | HMG-CoA reductase inhibitor | INHIBITOR | https://conductscience.org/library/genes/3156 |
Source ChEMBL
Diseases32
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 32Source Open Targets
See all 32 diseasesTrials58
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01976936 | Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2 | Phase 2 | 162 | 2025-12-01 | lovastatin | Its name | ClinicalTrials.gov |
| NCT00853580 | A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 | Phase 2 | 146 | 2018-03-12 | lovastatin | Its name | ClinicalTrials.gov |
| NCT00462280 | Lovastatin in Treating Patients At High Risk of Melanoma | Phase 2 | 80 | 2014-10-31 | lovastatin | Its name | ClinicalTrials.gov |
| NCT00580970 | Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury | Phase 2 | 73 | 2016-11-18 | lovastatin | Its name | ClinicalTrials.gov |
| NCT00302952 | Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis | Phase 2 | 64 | 2014-02-12 | lovastatin | Its name | ClinicalTrials.gov |
| NCT03763175 | Efficacy and Safety of SYN-010 in IBS-C | Phase 2 | 59 | 2021-09-05 | lovastatin | Its name | ClinicalTrials.gov |
| NCT00684723 | Fed Bioavailability Study of Lovastatin Tablets and Mevacor Tablets | Phase 1 | 54 | 2009-12-30 | lovastatin | Its name | ClinicalTrials.gov |
| NCT00685685 | Fasting Bioavailability Study of Lovastatin Tablets and Mevacor Tablets | Phase 1 | 54 | 2009-12-30 | lovastatin | Its name | ClinicalTrials.gov |
| NCT04359823 | DSAP Treatment Comparison: 2% Lovastatin/ 2% Cholesterol vs 2% Lovastatin Alone | Phase 1 | 31 | 2023-12-07 | lovastatin | Its name | ClinicalTrials.gov |
| NCT00285857 | Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention | Phase 2 | 30 | 2017-03-09 | lovastatin | Its name | ClinicalTrials.gov |
1 to 10 of 58
See all 58 trialsComparisons in its trials12
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Standard vs High Dose: Total Number of Participants With an Increase in Liver Function Tests (LFTs) | 1 of 81 | 2 of 81 | 162 | NCT01976936 | Trial comparisons |
| Lovastatin vs Placebo: deaths from any cause | 0 of 74 | 0 of 70 | 144 | NCT00853580 | Trial comparisons |
| Lovastatin vs Placebo: serious adverse events | 6 of 74 | 1 of 70 | 144 | NCT00853580 | Trial comparisons |
| Standard vs High Dose: Total Number of Participants With a Modified Rankin Score of 0-1 | 29 of 67 | 31 of 72 | 139 | NCT01976936 | Trial comparisons |
| Standard vs High Dose: Total Number of Participants With a Barthel Index Score > 95 | 46 of 65 | 38 of 70 | 135 | NCT01976936 | Trial comparisons |
| Lovastatin 40 mg Tablets vs Mevacor® 40 mg Tablets: serious adverse events | 0 of 54 | 0 of 54 | 108 | NCT00684723 | Trial comparisons |
| Lovastatin 40 mg Tablets vs Mevacor® 40 mg Tablets: serious adverse events | 0 of 53 | 0 of 52 | 105 | NCT00685685 | Trial comparisons |
| Lovastatin 80 mg vs Placebo: serious adverse events | 1 of 34 | 1 of 30 | 64 | NCT00302952 | Trial comparisons |
| Statin/Cholesterol Combination Group vs Statin Alone Group: deaths from any cause | 0 of 17 | 0 of 14 | 31 | NCT04359823 | Trial comparisons |
| Statin/Cholesterol Combination Group vs Statin Alone Group: serious adverse events | 0 of 17 | 0 of 14 | 31 | NCT04359823 | Trial comparisons |
1 to 10 of 12
See all 12 comparisons in its trialsPapers from its trials21
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials7
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Line Angle Matching | 2 | 1 | ConductCognition |
| Continuous Performance Test | 1 | 0 | ConductCognition |
| Go/No-Go Task | 1 | 0 | ConductCognition |
| Paired Associate Learning | 1 | 1 | ConductCognition |
| Stop-Signal Task | 1 | 0 | ConductCognition |
| Tower Planning | 1 | 0 | ConductCognition |
| Verbal Fluency | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL503
GET https://conductscience.org/api/drugs/v1/CHEMBL503/diseases?page=2